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Abstract
Pulmonary arterial hypertension is a fatal disorder of the lung circulation in which accumulation of vascular cells progressively
obliterates the pulmonary arterioles. This results in sustained elevation in pulmonary artery pressure leading eventually to right
heart failure. Approximately, 80% of familial and 20% of sporadic idiopathic pulmonary arterial hypertension cases are caused by
mutations in the bone morphogenetic protein receptor type 2 (BMPR2). Nonsense mutations in BMPR2 are amongst the most
common mutations found, where the insertion of a premature termination codon causes mRNA degradation via activation of the
nonsense-mediated decay pathway leading to a state of haploinsufficiency. Ataluren (PTC124), a compound that permits ribosomal
read-through of premature stop codons, has been previously reported to increase BMPR2 protein expression in cells derived from
pulmonary arterial hypertension patients harbouring nonsense mutations. In this study, we characterised the effects of PTC124 on
a range of nonsense BMPR2 mutations, focusing on the R584X mutation both in vitro and in vivo. Treatment with PTC124 partially
restored BMPR2 protein expression in blood outgrowth endothelial cells isolated from a patient harbouring the R584X mutation.
Furthermore, a downstream bone morphogenetic protein signalling target, Id1, was rescued by PTC124 treatment. Mutant cells
also exhibited increased lipopolysaccharide-induced permeability, which was reversed by PTC124 treatment. Increased prolifer-
ation and apoptosis in R584X blood outgrowth endothelial cells were also significantly reduced by PTC124. Moreover, oral
PTC124 increased lung BMPR2 protein expression in mice harbouring the R584X mutation (Bmpr2þ/R584X). Our findings provide
support for future experimental medicine studies of PTC124 in pulmonary arterial hypertension patients with specific nonsense
BMPR2 mutations.
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Introduction
Pulmonary arterial hypertension (PAH) is a devastating dis-
order characterised by excessive fibroblasts, endothelial cells
and smooth muscle cells in the lung vasculature. These aber-
rant cellular processes cause progressive occlusion of the
pulmonary arterioles leading to a sustained elevation in pul-
monary artery pressure and eventually right heart failure.
Current therapies slow disease progression while also alle-
viating symptoms, but the only cure remains lung
transplantation. Approximately 80% of families with
PAH, and 20% of apparently idiopathic PAH cases, are
due to autosomal dominant heterozygous germline
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mutations in the bone morphogenetic protein receptor type
2 (BMPR2).1–4 BMP signalling regulates many processes
related to growth, survival, differentiation and development.
Upon BMP ligand stimulation, the constitutively phos-
phorylated BMPR2 heterodimerises with BMP type I recep-
tors at the cell surface. A cascade of downstream signalling
occurs through phosphorylation of proteins known as recep-
tor-mediated Smads (R-Smads). R-Smads complex with
the common partner Smad, Smad4, and translocate to the
nucleus driving expression of target genes including the
family of inhibitors of DNA-binding (Ids 1–4).5 We have
previously shown that mutations in BMPR2 cause loss-of-
function with a reduction in expression of many down-
stream signalling targets, and altered growth responses to
BMP ligands.6–11
Nonsense mutations introduce premature stop codons
into the sequence of DNA. If the mRNA transcript is
expressed and translated, this can result in a truncated,
potentially non-functional protein. Alternately, the mutant
transcript is unstable and is rapidly removed by nonsense-
mediated mRNA decay (NMD),12 leading to complete
absence of the mutant protein. It is estimated that 12% of
known disease-causing mutations in the Human Gene
Mutation Database are due to nonsense mutations,13 but
the functional impact of the premature stop codon can be
difficult to predict. Previous studies proposed that variants
close to the 30 end of a transcript might avoid NMD.14
However, a recent large-scale RNA-seq study suggested
that up to 68% of variants predicted to cause NMD actually
escape RNA surveillance.15 Since the discovery of mutations
in BMPR2 predisposing individuals to PAH, over 300
distinct mutations have been identified with a significant
proportion due to nonsense mutations (approximately
30%).3,16,17
Aminoglycosides such as gentamicin have been used in
proof-of-concept studies to suppress NMD as a way of
treating cystic fibrosis (CF) and Duchenne muscular dystro-
phy (DMD).18–20 Indeed, gentamicin has been tested suc-
cessfully in premature termination codon (PTC) BMPR2
mutations models.21,22 However, the risk of renal and otic
toxicities due to the requirement of high doses have pre-
cluded the use of gentamicin as a therapeutic in this setting.
Ataluren (also known as PTC124) is a small molecule non-
aminoglycoside oxodiazole that promotes the read-through
of premature stop codons. Using a high-throughput discov-
ery screen, PTC124 was discovered and tested in vitro and
in vivo as a potentially safer alternative to gentamicin.23,24
In clinical trials for both CF and DMD, PTC124 appeared
safe and showed some promising efficiacy.24–26 Given these
promising findings, Drake et al. investigated the ability of
PTC124 to improve BMP signalling and reverse the hyper-
proliferative phenotype in nonsense mutant BMPR2 endo-
thelial cells.27
In this study, we further characterised the potential thera-
peutic properties of PTC124 on a range of PTCs across the
BMPR2 gene in patient-derived cells, and found major
differences in the restoration of BMPR2 protein expression
between BMPR2 mutations. Furthermore, we developed a
mouse knock-in model for one of these mutations (R584X)
to provide proof-of-concept that this approach might be
useful in vivo for specific BMPR2 nonsense mutations.
Materials and methods
Cell culture and treatments
Human blood outgrowth endothelial cells (BOECs) were
isolated from peripheral blood of PAH patients and healthy
controls as previously described.28–30 All blood donors pro-
vided informed consent in accordance with the human study
protocol – 07/H0306/134 (Cambridgeshire 3 Research
Ethics Committee). Cells were cultured and expanded in
Endothelial Cell Growth Medium-2 (EGM-2) (minus hep-
arin) (Lonza, Slough, UK) with 10% Foetal Bovine Serum
(FBS) (Thermo Fisher Scientific, Hemel Hempstead, UK).
All experiments were performed with passage 5–7 cells.
Human or mouse pulmonary artery smooth muscle cells
(PASMCs) were isolated as previously described and cul-
tured in DMEM (Invitrogen) containing 20% (v/v) FBS
and A/A (DMEM/20% FBS).31 The Royal Papworth
Hospital ethical review committee approved the use of the
human tissues (Ethics Ref 08-H0304-56þ 5), and informed
consent was obtained from all subjects. Recombinant
human BMP9 was purchased from R&D Systems
(Oxfordshire, UK). PTC124 was a kind gift from PTC
Therapeutics (South Plainfield, NJ, USA) and was used at
100mM overnight in all in vitro experiments.
Immunoblotting
Frozen lung tissue was homogenised in lysis buffer (250mM
Tris-HCl, pH6.8, 4% SDS, 20% v/v glycerol and
1EDTA-free protease inhibitor cocktail – Roche, West
Sussex, UK) and sonicated for approximately 1min and
then centrifuged for 15min at 15,000 g. BOECs were
lysed in lysis buffer (50mM Tris-HCl, pH8, 150mM
NaCl, 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS
and 1EDTA-free protease inhibitor cocktail). The protein
concentration was determined using the Bio-Rad Lowry
assay (Bio-Rad Laboratories, Hemel Hempstead, UK),
using Bovine Serum Albumin (BSA) as the standard. Cell
lysates (20–100 mg protein) were separated by SDS-PAGE
and proteins were transferred to polyvinylidene fluoride
membranes by semidry blotting (GE Healthcare,
Buckinghamshire, UK). Membranes were then blocked
and probed with a rabbit monoclonal antibody toward
Id1 (clone 195-14, CalBioreagents, San Mateo, CA) or a
mouse monoclonal antibody against BMPR2 (clone 18I,
BD Transduction Laboratories, Wokingham, Berkshire,
UK). After washing, blots were incubated with secondary
anti-mouse/rabbit horseradish peroxidase antibody (Dako,
Cambridgeshire, UK) for 1 h at room temperature. As a
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loading control, all blots were re-probed with a monoclonal
antibody for either a-tubulin (clone DM1A, Sigma-Aldrich)
or b-actin (clone AC-15, Sigma-Aldrich). Densitometry was
performed using ImageJ software. Membranes were devel-
oped using enhanced chemiluminescence (GE Healthcare).
Endothelial monolayer permeability
Monolayer permeability was assessed as described previ-
ously.32 Briefly, transwell inserts (Corning, Corning, NY)
were coated for 1 h at 37C with 0.1mg/ml bovine skin col-
lagen (Sigma), washed twice with water and rinsed with
medium before plating cells. BOECs (400,000 cells in
100 ml Complete EGM-2 medium) were plated in the top
chamber and 700 ml of medium was added to the bottom
chamber 24 h before addition of fresh medium to both
chambers, with or without 5 ng/ml BMP9 or PTC124
(100mM) in the upper chamber. After 30min, 25 nM horse-
radish peroxidase (HRP) was added to the top chamber,
with or without 0.4 mg/ml lipopolysaccharide (LPS)
(Sigma). Medium (20 ml) was collected from the lower cham-
ber every 15min for 60min. The HRP content of this
medium was determined by measuring absorbance at
490 nm after the addition of 150 ml of o-phenylenediamine
dihydrochloride buffer to each well of a 96-well plate.
Cell proliferation
For assessment of BOEC proliferation, cells were seeded at
40,000 cells/well in 24-well plates and left to adhere over-
night. After 24 h, cells were then exposed to the stated treat-
ments in EBM-2 containing 2% FBS and A/A. Treatments
were replenished every 48 h. For assessment of mouse
PASMC proliferation, cells were seeded at 30,000 cells/well
in 24-well plates and left to adhere overnight. After
24 h, cells were then exposed with or without
PTC124 100mM in complete culture media for 48 h. At the
relevant time points, cells were trypsinised and counted on a
haemocytometer using trypan blue exclusion to assess cell
viability.
Apoptosis
Prior to addition of an apoptotic stimulus, BOECs were
transferred into EBM-2 basal media (Lonza) with 2%
FBS, 100 U/ml penicillin, 100mg/ml streptomycin and
0.25mg/ml amphotericin B, but without any growth factor
supplements for 16 h. During this incubation, cells were
maintained with or without PTC124 (100mM) for the indi-
cated period. Following the 16 h incubation, cells were either
left unstimulated or treated for 6 h with 10 ng/ml Tumour
Necrosis Factor-a (TNFa) and 20 mg/ml cycloheximide to
induce apoptosis. Following the apoptotic stimulus, cells
were trypsinised and stained with FITC-conjugated annexin
V and propidium iodide (PI, BD Biosciences, Wokingham,
UK) as per the manufacturer’s instructions and assessed by
flow cytometry. Apoptotic cells were defined as positive for
Annexin-V staining and negative for PI staining.
RNA preparation and quantitative reverse transcriptase
polymerase chain reaction
Total RNA was extracted using the RNeasy Mini Kit with
DNAse digestion (Qiagen, West Sussex, UK). cDNA was
prepared from 1 mg of RNA using the High Capacity
Reverse Transcriptase kit (Applied Biosystems, California,
USA), according to the manufacturer’s instructions. All
qPCR reactions were prepared in MicroAmp optical 384-
well reaction plates (Applied Biosystems) using 50 ng/ml
cDNA with SYBRGreen JumpstartTM Taq ReadymixTM
(Sigma-Aldrich), ROX reference dye (Invitrogen) and sense
and anti-sense primers (all 200 nM). Primers for human:
BMPR2, ACTB; mouse: Bmpr2, Actb, B2m and Hprt were
all designed using Primer3 (http://primer3.sourceforge.net/).
Reactions were amplified on a QuantStudio 6Flex Real-
Time PCR system (Applied Biosystems). In human
BOECs, target gene expression was normalised to ACTB
and the difference in the amount of product produced was
expressed as a fold change. Relative expression of each
target gene was identified using the comparative 2-(Ct)
method. In mouse lung, target gene expression was normal-
ised to Actb, B2m and Hprt and the difference expression
represented as relative expression.
Puromycin incubation and RNA isolation
The following protocol was adapted from Hamid and col-
leagues.22 BOECs or PASMCs were cultured in full growth
media in 6 cm dishes until confluence and then incubated
with or without puromycin (100mg/ml, Sigma Aldrich)
16 h prior to harvesting. RNA was harvested using the
RNeasy Mini kit (Qiagen) following the manufacturer’s
instructions.
Reverse transcriptase polymerase chain reaction
of BMPR2
Total RNA (3 mg) was used as a template for cDNA syn-
thesis. Following the manufacturer’s protocol, first-strand
cDNA synthesis was performed using SuperScriptTM First-
Strand System (Thermo Fisher Scientific) with an oligo-dT
primer. A tenth of the first-strand reaction volume was then
used as a template for PCR amplification. Reverse tran-
scriptase polymerase chain reaction (RT-PCR) primers
were as follows: W9X – CTTTGCCCTCCTGATTCTT
GG (forward) and CTGCTGCCTCCATCATGTTC
(reverse); R213X – GAACATGATGGAGGCAGCAG
(forward) and CTCGATGGGAAATTGCAGGT
(reverse); R321X – CACCACTCAGTCCACCTCAT (for-
ward) and GCGCACCAGTCTATTTCCAG (reverse);
R584X – AGACTGTTGGGACCAGGATG (forward)
and CGTGAGTCCTGTGGTGTTTG (reverse); R899X –
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CAACAAGCTGGCCATGATGA (forward) and
TGCAAGGTAAACAGCAGTGC (reverse). RT-PCR
amplification was conducted using the ElongaseTM
Enzyme Mix (Thermo Fisher Scientific). Cycling parameters
were as follows: initialisation step – 30 s at 94C; amplifica-
tion step (55 cycles) – 94C for 30 s, 58C for 30 s, 68C for
3min 30 s; extension step – 68C for 5min. cDNA products
were visualised by agarose gel electrophoresis.
DNA sequencing of RT-PCR products
Prior to sequencing, BMPR2 RT-PCR products were pur-
ified with ExoSAP-ITTM PCR Product Cleanup reagent
(Thermo Fisher Scientific) according to the manufacturer’s
protocol. Sequencing reactions were performed using the
BigDyeTM Terminator v3.1 Cycle Sequencing kit (Thermo
Fisher Scientific) according to the manufacturer’s protocol.
Samples were then sequenced.
Bmpr2þ/R584X knock-in mouse model
For all animal work, group sizes were determined using esti-
mates of variance and minimum detectable differences
between the groups that were based on our past experience
with rodent models of PAH. Animals were randomised
using an assigned animal identification number, allowing
investigators performing all cardiopulmonary phenotyping
procedures and histological analyses to be blinded to animal
genotype and treatment group. All animal work was carried
out in accordance with the UK Animals (Scientific
Procedures) Act 1986 and approved under Home Office
Project License 80/2460.
The Bmpr2þ/R584X knock-in mouse model was generated by
GenOway (Lyon, France). Supplementary Fig. 5 depicts an
overview of the strategy used to generate the R584X mutant.
A targeting vector containing the R584X mutation in exon 12
was generated. Upstream of the 30 short homology arm a lox-
P flanked neomycin cassette was inserted. PCR screening and
Southern blot screening were conducted to detect homologous
recombination after electroporation into embryonic stem (ES)
cells. Sequence analysis was then conducted to ascertain pres-
ence of the R584X mutation. Recombined ES cell clones were
injected into blastocysts. To generate chimeric male carrying
the recombined locus, blastocysts were implanted in pseudo-
pregnant females and allowed to develop to term. Chimerism
was assessed based on coat colour. Chrimeric males were then
bred with Cre-deleter mice to excise the loxP-flanked neomycin
cassette. Progeny was assessed by genotype analysis.
PTC124 treatment of Bmpr2þ/R584X animals
Littermate controls (Bmpr2þ/þ; n¼ 12) and R584X knock-in
(Bmpr2þ/R584X; n¼ 12) mice were randomised into two
groups. One group was fed chow supplemented with
PTC124 (0.3% PTC124) supplied by PTC Therapeutics
(South Plainfield, NJ, USA) for two weeks. The other
group was fed a standard chow diet for two weeks. Mice
were anesthetised with isoflurane inhalation and then either
assessed haemodynamically or mice were exsanguinated and
the lungs were removed for further analysis. Lungs were
either fixed in situ in the distended state by infusion of
10% buffered formalin into the pulmonary artery (at 25
mmHg pressure) via the trachea and overnight fixation in
4% formalin prior to embedding in paraffin, or immediately
frozen in liquid nitrogen for protein or RNA isolation.
Where indicated in the relevant results section, catheter-
isation of the right ventricle (RV) was undertaken via can-
nulation of the right internal jugular vein using a Millar
SPR-139 catheter (Millar Instruments, Houston, TX) con-
nected to PowerLab hardware utilising LabChart 8
(ADInstruments, Oxford, UK). Mice were then sacrificed
and the hearts and lungs were harvested. Right ventricular
hypertrophy (RVH) was assessed by removing the heart and
dissecting the RV free wall from the left ventricle plus
septum (LVþ S) and weighing separately. The degree of
RVH was determined from the ratio RV/LVþ S.
Assessment of pulmonary vascular remodelling
In order to assess pulmonary arteriolar muscularisation, sec-
tions of fixed mouse lung tissue (5 mm in thickness) were
labelled with monoclonal mouse-anti-smooth muscle
a-actin (SMA) (clone 1A4, Dako, Glostrup, Denmark), fol-
lowed by polyclonal goat anti-mouse HRP. To detect stain-
ing, the Dako ARKTM kit (Dako) was used in accordance
with the manufacturer’s instructions. Antibody staining was
visualised using 3-3’ diaminobenzidine hydrochloride as
substrate-chromogen and counterstained with Carrazzi
haematoxylin. Pulmonary arteriolar muscularisation was
assessed by the identification of alveolar ducts and categor-
isation of the accompanying intra-acinar artery as non-, par-
tially or fully muscularised, by the degree of SMA
immunostaining. A minimum of 20 vessels with diameters
ranging from 25 to 75 mm were categorised as either fully,
partially or non-muscularised. Assessment of muscularisa-
tion was performed in a blinded fashion by a single
researcher, to reduce operator variability, who was not
aware of the group allocation of the samples being analysed.
PTC124 measurement in serum
PTC124 concentration in mouse serum was conducted
using Liquid Chromatography with Mass Spectrometry
(LC/MS/MS). Serum was isolated from blood samples col-
lected in EDTA tubes at days 7 and 14 by tail vein bleed.
Blood samples were centrifuged at 2000 g for 5min, and
the serum fraction was extracted and stored at 80C.
Samples were analysed using LC/MS/MS by PTC
Therapeutics using a UPLC I-Class System and Xevo TQ-
S Spectrometer (Waters Corporation, Milford, MA, USA).
Briefly, a standard curve of PTC124 was generated (0.01–
5 lg/ml). Samples were diluted with 16% methanol and
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1 mg/ml D4-124 in acetonitrile. Samples were placed on an
automatic shaker for 5min before centrifugation at 2000 r/
min for 2min prior to injecting onto the LC/MS/MS system.
Statistics
All data were analysed using GraphPad Prism. Data are
presented as mean SEM. Data were analysed by one-
way/two-way ANOVA with post-hoc Tukey’s honestly sig-
nificant difference (HSD) analysis or paired two-tailed
Student’s t-test where indicated. P< 0.05 was considered
significant.
Results
Reduced BMPR2 protein expression in BOECs from
patients harbouring nonsense BMPR2 mutations
versus controls
BOECs were available from four patients with nonsense
mutations in BMPR2 (W9X, R213X, R321X and R584X),
and one patient with a missense mutation in the kinase
domain of BMPR2 (C347R). A further PASMC line was
available from a PAH patient with a nonsense BMPR2
mutation (R899X) (Supplementary Fig. 1 and Table 1).
BMPR2 protein expression was assessed in BOECs from
control subjects and BMPR2 mutant PAH patients. In all
mutation patients, BMPR2 protein expression was signifi-
cantly reduced when compared to BOECs isolated from
controls (Fig. 1a and b). In addition, BMPR2 mRNA
expression in nonsense BMPR2 mutations was significantly
reduced (Fig. 1c).
NMD contributes to reduced expression of mutant
transcripts
The reduced mRNA and protein expression and the absence
of truncated BMPR2 protein species is consistent with the
mutations giving rise to an unstable mRNA transcript that
is susceptible to NMD, leading to a state of haploinsuffi-
ciency. To assess the abundance of wild-type and mutant
mRNA species, heterozygous mutant BOECs from PAH
patients were used. The relative abundance of wild-type
and mutant transcripts was assessed by sequencing of
cDNA following RT-PCR. In general, all nonsense muta-
tions gave rise to a greatly reduced level of mutant tran-
script, as evidenced by very low chromatogram signals
(Fig. 1d and e; Supplementary Fig. 2a and c). The level of
mutant transcript varied between mutations with R584X
showing the highest transcript level and W9X the lowest.
To demonstrate whether NMD was contributing to the
reduced mutant transcript level, BOECs were treated with
puromycin to suppress NMD. Treatment with puromycin
increased transcripts of the mutant alleles for all mutations
(Fig. 1d and e; Supplementary Fig. 2a) except W9X
(Supplementary Fig. 2c). We also assessed the effect of
puromycin treatment in PASMCs harbouring a R899X
mutation. The baseline R899X transcript level was also
greatly reduced, but increased following treatment with
puromycin (Supplementary Fig. 2b). In Table 2, the pre-
dominant transcript is highlighted in bold and the relative
fold-change of the mutant transcript versus the wild-type is
detailed, puromycin treatment.
PTC124 treatment improves BMPR2 protein expression
and downstream signalling in R584X cells
BOECs harbouring heterozygous R213X, R321X and
R584X mutations were treated with PTC124 (100 mM) for
24 h. BMPR2 protein expression was significantly increased
by PTC124 in R584X mutant cells but not in R213X or
R321X cells (Fig. 2a and b). It is worth noting that
PTC124 had no effect upon BMPR2 protein expression in
control BOECs (Supplementary Fig. 3). Furthermore,
PTC124 consistently increased Id1 protein levels as a
marker of BMPR2 signalling in R584X mutant BOECs
(Fig 2c and d). No effect on Id1 levels was observed in con-
trol BOECs (Supplementary Fig. 3).
Endothelial dysfunction in the R584X mutant is
restored by PTC124 treatment
We next questioned whether PTC124 could restore the func-
tional impact of BMPR2 mutation on endothelial cells.
First, we examined the effect of PTC124 on endothelial bar-
rier integrity. Monolayer integrity was determined by mea-
suring the amount of horseradish peroxidase leak into the
bottom chamber in transwell experiments. Consistent with
the results of our previous studies,11 BMP9 treatment inhib-
ited LPS-induced monolayer permeability in both wild-type
and BMPR2 mutant cells (Fig. 3a and b; Supplementary
Fig. 4a and b). Furthermore, the BMPR2 mutant BOECs
demonstrated greater permeability in the presence of LPS
compared to wild-type cells (Fig. 4a and b; Supplementary
Fig. 4a and b). Treatment with PTC124 had no effect on
monolayer integrity after LPS stimulation in wild-type or
R321X BOECs (Fig. 3a; Supplementary Fig. 4a and b).
However, in R584X BOECs, PTC124 alone significantly
reduced the LPS-induced permeability (Fig. 3b).
Since increased endothelial apoptosis is considered a crit-
ical response to injury in BMPR2 mutant endothelial cells,
we next examined the effect of PTC124 treatment on apop-
tosis. As previously reported,11 we observed that BOECs
harbouring BMPR2 mutants demonstrate an increased sus-
ceptibility to TNFa-induced apoptosis (Fig. 4a;
Supplementary Fig. 5a). Only BOECs with the R584X
mutation showed reduced apoptosis when treated with
PTC124 (Fig. 4a). TNFa-induced apoptosis in BOECs har-
bouring the R321X mutation was unaffected by treatment
with PTC124 (Supplementary Fig. 5a).
Finally, we assessed the hyperproliferation of mutant
BOECs and the effect of PTC124 treatment. Our group
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Fig. 1. Puromycin treatment increases BMPR2 R584X mutant transcript. (a) Protein lysates were extracted from blood outgrowth endothelial
cells (BOECs) from wild-type (n¼ 3) and BMPR2 mutant (n¼ 5) patients. Lysates were immunoblotted for BMPR2 and loading control, a-tubulin.
(b) Densitometry analysis of the ratio between BMPR2 and a-tubulin. (c) BMPR2 mRNA expression of BOECs harbouring nonsense mutations
was assessed and normalised to ACTB. (d and e) BOECs harbouring a R584X or R321X were treated overnight with puromycin (100mg/ml).
Following RNA isolation, amplified RT-PCR products were sequenced. Chromatograms for R584X (d) and R321X (e) show the effects of
puromycin treatment on transcript expression. One-way ANOVA. *P 0.05. Error bars represent mean SEM.
BMPR2: bone morphogenetic protein receptor type 2.
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has previously shown that BOECs with BMPR2 deficiency
are hyperproliferative.9 Both BOECs harbouring the R321X
and R584X mutations exhibited hyperproliferation when
compared to wild-type BOECs (Fig. 4b; Supplementary
Fig. 5b). Again, only the R584X mutation was significantly
affected by PTC124 treatment with a similar reduction in
hyperproliferation compared to BMP9 treatment (Fig. 4b).
Only BMP9 treatment significantly reduced hyperprolifera-
tion in R321X mutant cells (Supplementary Fig. 5b).
PTC124 improves BMPR2 protein expression in a R584X
mouse model
Given that PTC124 exerted promising effects on endothelial
function and BMPR2 protein expression in vitro, we devel-
oped a knock-in mouse harbouring a heterozygous R584X
mutation (Bmpr2þ/R584X) (Supplementary Fig. 6) to test the
effects of PTC124 in vivo. Similar to the findings in patient-
derived BOECs, BMPR2 protein and mRNA was signifi-
cantly reduced in the Bmpr2þ/R584X mouse lungs compared
to littermate controls (Fig. 5a, b and e). Mutant Bmpr2þ/
R584X and littermate controls were fed either standard chow
or chow supplemented with 0.3% PTC124 over a two-week
period. Treatment with PTC124 significantly increased
BMPR2 protein expression in Bmpr2þ/R584X mouse lungs
(Fig. 5a and d), with no effect observed in wild-type animals
(Fig. 5a and c). Furthermore, mRNA levels in either wild-
type or R584X mutant animals in the presence of PTC124
remained unaffected (Fig. 5f and g).
To confirm that mice provided with PTC124 chow
attained plasma levels of PTC consistent with a pharmaco-
logical effect,24 blood samples were taken at 7 and 14 days
for measurement of PTC124 using mass spectrometry. Both
mutant and control animals had similar levels of PTC124 at
7- and 14-days treatment (Fig. 5h). PTC124 levels was
undetectable in control animals fed standard chow
(<0.02mg/ml).
No differences were identified in either right ventricular
systolic pressure, RVH or vascular remodelling at six
months of age (Supplementary Fig. 7a, b and c).
Interestingly, during the breeding of this mouse line, we
noted that parental heterozygous mating occasionally gave
rise to homozygous Bmpr2R584X/R584X mice. Given that
homozygous Bmpr2–/– usually die in utero, this further sug-
gests that the R584X mutation may have a lower impact on
BMPR2 function than other mutations.33
PTC124 inhibits hyperproliferation in Bmpr2þ/R584X
PASMCs
One well recognised phenotype of human and mouse
BMPR2 mutant PASMCs is heightened proliferation in
serum.34,35 Consistent with this, PASMCs derived from
Bmpr2þ/R584X mice exhibited increased cell number in the
presence of serum after six days in culture (Fig. 6).
Culture of Bmpr2þ/R584X PASMCs in the presence of
PTC124 effectively attenuated the hyperproliferation, with
no impact on the proliferation rate of PASMCs from wild-
type mice.
Discussion
Nonsense mutations account for approximately 30% of
BMPR2 mutations underlying heritable PAH.16 We have
previously proposed that correcting premature stop
codons introduced by these mutations might be an approach
to treat patients with PAH who carry these mutations.27
Ataluren (PTC124) has been used in clinical trials in the
treatment of CF and DMD promoting translational read-
through of truncating mutations in CF transmembrane
conductance regulator (CFTR) and dystrophin, respect-
ively.24–26 Our findings suggest that nonsense mutations in
Table 2. Puromycin treatment of BMPR2 mutant BOECs.
Wild-type
allele Mutant allele
Puromycin
negative
Ratio of M/W
(fold change)
Puromycin
positive
Ratio of M/W
(fold change)
W9X TGG TGA TGG 0.079 TGG 0.106
R213X CGA TGA CGA 0.154 CGA 0.609
R321X CGA TGA CGA 0.153 CGA 0.568
R584X CGA TGA CGA 0.587 TGA 1.697
R899X CGA TGA CGA 0.259 CGA 0.545
Note: The fold change is calculated by the ratio of the mutant allele peak height/wild-type peak height in the appropriate chromatograms.
Table 1. Demographics of BMPR2 mutant BOECs.
Gender Age Ethnicity mPAP
W9X Female 35 Caucasian 65
R213X Female 36 Asian 40
R321X Male 45 Caucasian 46
R584X Female 79 Caucasian 52
R899X Female 30 N/A N/A
C347R Male 27 Caucasian N/A
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Fig. 2. PTC124 treatment increases BMPR2 protein expression and downstream signalling in R584X mutant BOECs. (a) BOECs isolated from
patients harbouring R213X, R321X and R584X were treated with either PTC124 (100 mM) for 24 h. Lysates were immunoblotted for BMPR2 and
loading control, a-tubulin (n¼ 3). (b) Densitometry analysis of the ratio between BMPR2 and a-tubulin. (c) R584X mutant BOECs were treated
with PTC124 (100 mM) for 24 h. Representative immunoblot for Id1 and loading control, a-tubulin (n¼ 3). (d) Densitometry analysis of the ratio
of a-tubulin compared to Id1 (n¼ 3). Student’s t-test. *P 0.05. Error bars represent mean SEM.
BMPR2: bone morphogenetic protein receptor type 2.
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BMPR2 that lead to the introduction of a PTC trigger
robust NMD and do not lead to the expression of a trun-
cated BMPR2 protein. In fact, the impact of NMD is such
that the mutant BMPR2 transcripts are generally expressed
at a very low level. This is of major importance for thera-
peutic approaches, such as PTC124, that act by enhancing
translational read-through of the mRNA. In the absence of
BMPR2 mRNA, these drugs lack the substrate to initiate
ribosomal translation into protein. Nevertheless, we identi-
fied at least one BMPR2 mutation, R584X, that demon-
strated measurable levels of mRNA. In this specific case,
we were able to show that PTC124 increased the expression
of BMPR2 protein and downstream signalling both in vitro
and in vivo.
We have previously established a number of functional
assays such as vascular permeability, apoptosis and
proliferation to test the effectiveness of BMP9 treatment
on endothelial cell function.11 Using these methods, we
assessed the ability of PTC124 to rescue the R584X
mutant BOECs. We compared cells harbouring the R584X
mutation with BOECs expressing R321X, a BMPR2 muta-
tion that previously showed little or no increase in BMPR2
protein expression following PTC124 treatment. Both cell
Fig. 3. PTC124 treatment promotes monolayer integrity in R584X
mutant BOECs. Permeability was assessed in monolayers of wild-type
(a) (n¼ 3) and R584X mutant (b) (n¼ 3) BOECs treated with either
PTC124 (100 mM) or BMP9 (5 ng/ml) and/or LPS (400 ng/ml).
Colorimetric absorbance of HRP was measured after incubation per-
iods every 15min until 1 h. One-way ANOVA. *P 0.05. Error bars
represent mean SEM.
LPS: lipopolysaccharide; PTC: premature termination codon. Fig. 4. PTC124 treatment prevents apoptosis and hyperproliferation
in R584X mutant BOECs. (a) Quantification of apoptotic (Annexin-Vþ/
PI–) wild-type (n¼ 3) and R584X mutant BOECs (n¼ 3) after PTC124
treatment for 24 h prior to the addition of TNFa (10 ng/ml) and
cycloheximide (20microgram/ml) for six hours. (b) Proliferation
assessment of wild-type (n¼ 3) and R584X mutant (n¼ 3) BOECs
after day 6, following PTC124 (100 mM) or BMP9 (5 ng/ml) treatment.
One-way ANOVA. *P 0.05, **P 0.01, ***P 0.001, ****P 0.0001.
Error bars represent mean SEM.
PTC: premature termination codon; BMP: bone morphogenetic
protein.
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Fig. 5. PTC124 treatment rescues low BMPR2 protein expression. Littermate controls (Bmpr2þ/þ) and R584X knock-in (Bmpr2þ/R584X) mice were
randomised into two treatment groups. One group was fed chow supplemented with PTC124 and the other group were fed a standard chow diet
for two weeks. (a) Lungs were isolated from wild-type (Bmpr2þ/þ) (n¼ 3); wild-type plus PTC124 (Bmpr2þ/þþ PTC124) (n¼ 3); R584X knock-in
(Bmpr2þ/R584X) (n¼ 3); R584X knock-in (Bmpr2þ/R584Xþ PTC124) (n¼ 3). Protein lysates were extracted and immunoblotted for BMPR2 and
loading control, a-tubulin (n¼ 3). (b) Densitometry analysis of the ratio between BMPR2 and a-tubulin in Bmpr2þ/þ versus Bmpr2þ/R584X. (c)
Densitometry analysis of the ratio between BMPR2 and a-tubulin in Bmpr2þ/þ versus Bmpr2þ/þþ PTC124. (d) Densitometry analysis of the ratio
between BMPR2 and a-tubulin in Bmpr2þ/R584X versus Bmpr2þ/R584Xþ PTC124. (e to g) Lungs were isolated from wild-type (Bmpr2þ/þ) (n¼ 7);
wild-type plus PTC124 (Bmpr2þ/þþ PTC124) (n¼ 4); R584X knock-in (Bmpr2þ/R584X) (n¼ 7); R584X knock-in (Bmpr2þ/R584Xþ PTC124) (n¼ 3).
Bmpr2 mRNA expression was assessed and normalised to three endogenous controls (Actb, B2m and Hprt). (h) PTC124 levels was measured by MS/
LC/LC in the serum of PTC124 treated animals at day 7 and day14. Student’s t-test. *P 0.05, **P< 0.01, ****P< 0.0001. Error bars represent
mean SEM.
PTC: premature termination codon; BMPR2: bone morphogenetic protein receptor type 2.
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lines exhibited increased vascular permeability compared to
the wild-type controls in the presence of LPS which was
abrogated by BMP9 treatment. Only cells expressing
R584X mutation responded to PTC124 treatment. Of
note, no differences were observed with combined BMP9
and PTC124 treatment. Furthermore, the significant
increase in apoptosis in both mutant cell lines was only
normalised by PTC124 treatment in the R584X BOECs.
Similarly, the hyperproliferation phenotype of both
BMPR2 mutants was only corrected by PTC124 in the
R584X mutant line. Interestingly, BMP9 attenuated the
increased proliferation in both BMPR2 mutant cells.
Given these findings, a knock-in R584X mouse model
was established. Unfortunately, a lack of haemodynamic
or vascular remodelling phenotype was observed in the
model. Our experience with other genetic mouse models
such as the C118W knock-in mouse, the R899X knock-in,
or Bmpr2 heterozygous null mouse is that these animals
develop mild or no pulmonary hypertension, sometimes
age-related, but do exhibit morphological evidence of pul-
monary vascular remodelling.11,34,36 Therefore, the lack of a
pulmonary hypertension phenotype in the Bmpr2þ/R584X
mouse model is not unexpected. It was more surprising
that the mouse exhibited no evidence of pulmonary vascular
remodelling. One explanation is that the deficiency of Bmpr2
in this mouse is less profound than in other Bmpr2 deficient
models. This is supported by the appearance of homozygous
Bmpr2R584X/R584X mice in our breeding colony.
Nevertheless, the Bmpr2þ/R584X mouse proved a useful
model to demonstrate proof-of-concept and target engage-
ment in the presence of PTC124. Correction of molecular
phenotypes was observed in these animals in the presence of
PTC124. First, PTC124 was administered in the diet and
serum levels indicated therapeutic levels of the drug at
weeks 1 and 2 post administration in both wild-type and
Bmpr2þ/R584X mice. Similar to our in vitro observations in
human BOECs, Bmpr2 protein and mRNA expression was
significantly reduced in the mutant animals. Treatment with
the PTC124 significantly enhanced Bmpr2 protein expres-
sion. Furthermore, PTC124 reduced the hyperproliferation
of PASMCs isolated from the R584X mutant mouse model.
It appears that PTC124 may have a limited therapeutic
role for PAH patients harbouring nonsense mutations in
BMPR2. The reasons for this could include the efficiency
of NMD triggered by these different mutations. The dis-
ease-causing PTC mutations we investigated were localised
to four domains of the BMPR2 protein – extracellular,
transmembrane, kinase and cytoplasmic tail domain.
However, the impact and efficiency of NMD are hard to
predict. The most commonly proposed mechanism of
NMD is the canonical exon junction complex (EJC)
model.37,38 Ordinarily, EJC proteins bind at exon–exon
junctions until they are stripped from mRNAs by the trans-
lating ribosome following nuclear export. However, if a
PTC is present 50 nucleotides upstream of the last exon
boundary, then the EJC remains bound triggering NMD.
A proposed exception to this model occurs when PTC tran-
scripts in close proximity to the start codon circumvent
NMD by reinitiating translation.39,40 Lindeboom and col-
leagues used matched exome and transcriptome data from
over 9000 human tumours to further understand the prin-
ciples governing NMD.41 First, in the human tumour data,
the NMD efficiency correlated with the proximity of the
PTC to the start codon and the last exon.41 Second, signifi-
cant reduction in NMD was observed in PTCs that were
found in the extremely long exons. Furthermore, the dis-
tance between PTC and the downstream exon junction
leads to lower degradation rates.41 Applying the rules to
the PTC mutations we tested in BMPR2 may go some
way to deciphering why R584X is more susceptible to treat-
ment with PTC124. All mutations tested were 50 nucleotides
upstream of the last exon boundary. Only R584X and
R899X are located in an exceptionally long exon (exon
12), and the R584X mutation is furthest away from the
normal translational stop codon. Therefore, this could
make the R584X mutation more likely to be less efficient
at NMD.
DMD is caused by mutations in the dystrophin protein.
More than 7000 mutations are associated with either DMD
or Becker muscular dystrophy.42 As the largest human gene,
DMD is susceptible to a high mutation rate, which underlies
the large variation of mutations detected in the gene. The
majority of DMD patients have deletions or duplications in
Fig. 6. Bmpr2þ/R584X PASMCs hyperproliferation is rescued by
PTC124 treatment. Mouse PASMCs were isolated from lungs of wild-
type or R584X mutant animals. Proliferation assessment of Bmpr2þ/þ
(n¼ 3) and Bmpr2þ/R584X (n¼ 3) PASMCs after day 6, following
PTC124 (100 mM) treatment. One-way ANOVA. *P 0.05. Error bars
represent mean SEM.
PTC: premature termination codon; BMPR2: bone morphogenetic
protein receptor type 2.
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one or more exons, but a small proportion of patients are due
to small insertions or deletions (20%) with a number due to
nonsense mutations inserting a premature stop codon with
approximately 10% of dystrophinopathies due to nonsense
mutations.43 In a phase 2b controlled trial, PTC124 was
shown to slow disease progression, in boys 5 years with a
nonsense mutation dystrophinopathy, using the six-minute
walk distance (6MWD) as the primary endpoint.44
However, in a subsequent phase 3 randomised, double-
blinded trial with PTC124, there was no significant difference
between the placebo and treated groups based on 6MWD.45
However, the authors of this study proposed that clinical
significance was reached in a subgroup of patients. The
authors concluded that ongoing trials should be conducted
to assess the long-term benefits and safety of PTC124.
The efficacy of PTC124 has been assessed in CF. In
approximately 5–10% of CF patients, nonsense mutations
in the gene encoding the CFTR are causative of disease46
and exhibit a severe clinical phenotype.47 A preclinical inves-
tigation suggested that PTC124 improved the generation of
functional CFTR in an animal model of CF due to a nonsense
mutation (G542X).48 Also, a short-term proof-of-concept
trial in patients with nonsense mutations improved epithelial
electrophysiological abnormalities caused by dysfunctional
CFTR.25 An extended 12-week study with PTC124 in 19
patients with at least one CFTR nonsense mutation improved
total chloride transport.26 Furthermore, improved CFTR
function was associated with improved pulmonary function
and reduced CF-related coughing. However, in 2017, PTC
therapeutics abandoned a 48-week phase 3 clinical trial as
the two primary endpoints were un-met.49
Overall, the clinical trials for both CF and DMD pro-
vided inconclusive evidence for the effectiveness of PTC124
as a therapy. However, every study reported that the drug
was well tolerated with few toxic side effects. As discussed
above, the rules governing NMD are complex and efficiency
depends on the location of the PTC in the gene. As we have
shown in this study, it is possible that PTC124 could provide
benefit to a specific subset of PAH patients where NMD is
less efficient. For example, apart from R584X, there are
seven nonsense mutations (Y543X, R597X, Q657X,
E661X, E672X, Y708X and Q720X) in exon 12 of
BMPR2 that might be benefited by drugs that enhance
translational read-through.3,17,50 The availability of
BOECs derived from patients provides an opportunity to
test in vitro whether individual BMPR2 mutations might
benefit from PTC124. This approach could be used as a
biomarker in experimental medicine studies and to select
patients for inclusion in clinical trials.
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